Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382265 | 1.00 | TRPV1 (0.68) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL15358922 | 0.91 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL14329163 | 0.87 | TRPV1 (0.53) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5923227 | 0.86 | TRPV1 (0.73) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL20036237 | 0.86 | TRPV1 (0.62) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5923219 | 0.86 | TRPV1 (0.73) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL2210228 | 0.86 | LTA4H (0.53) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL14092947 | 0.86 | ALDH1A1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL6002616 | 0.86 | ALDH1A1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL16407907 | 0.85 | TRPV1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9420817-B2 | Agent for amelioration of dysphagia, and pharmaceutical or food composition comprising the same | AJINOMOTO CO., INC. (JP) | 2016-08-23 | — | — | US | claimed |
| EP-1627634-B1 | Use of capsinoids for the treatment of arteriosclerosis | AJINOMOTO KK (JP) | 2013-10-16 | — | — | EP | claimed |
| US-20120251516-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | PROPANC PTY Ltd. (AU) | 2012-10-04 | — | — | US | claimed |
| WO-2011047434-A1 | A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | PROPANC PTY LTD (AU) | 2011-04-28 | — | — | WO | claimed |
| JP-11246478-A | — | — | None | — | — | JP | disclosed |
| US-20240216304-A1 | CAPSAICIN AND TRPV1 MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216304-A1 | CAPSAICIN AND TRPV1 MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-07-04 | — | — | US | disclosed |
| US-11773055-B2 | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs | CHORDA PHARMA, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773055-B2 | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs | CHORDA PHARMA, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | PROPANC PTY LTD (AU) | 2023-05-04 | — | — | US | disclosed |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | PROPANC PTY LTD (AU) | 2023-05-04 | — | — | US | disclosed |
| US-20080182894-A1 | METHOD OF PROVIDING PREPARATION FOR TOPICAL APPLICATION AND SUPPLEMENT MEETING CLIENT'S NEEDS | AJINOMOTO CO., INC. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080182894-A1 | METHOD OF PROVIDING PREPARATION FOR TOPICAL APPLICATION AND SUPPLEMENT MEETING CLIENT'S NEEDS | AJINOMOTO CO., INC. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1917961-A1 | CAPSINOID CONTAINING COMPOSITION | Ajinomoto Co., Inc. (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20070264411-A1 | PROCESS OF PRODUCING A CAPSINOID-CONTAINING FOOD AND DRINK | AJINOMOTO CO., INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070264411-A1 | PROCESS OF PRODUCING A CAPSINOID-CONTAINING FOOD AND DRINK | AJINOMOTO CO., INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070020738-A1 | produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production | AJINOMOTO CO., INC (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070020738-A1 | produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production | AJINOMOTO CO., INC (JP) | 2007-01-25 | — | — | US | disclosed |
| JP-H11246478-A | NEW CAPSAICINOID-LIKE MATERIAL HAVING ESTER BOND | MORINAGA & CO LTD | 1999-09-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251516-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT | SPINT2, PRSS1, SERPINB1 | TRPV1 505/4885CYP1A2 1917/4885CYP3A4 659/4885 |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | SPINT2, PRSS1, SERPINB1 | TRPV1 505/4885CYP1A2 1917/4885CYP3A4 659/4885 |
| US-11773055-B2 | Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs | HCAR2, HCAR3, TRPV1 | TRPV1 3/4885CYP1A2 910/4885CYP3A4 588/4885 |
| US-20240216304-A1 | CAPSAICIN AND TRPV1 MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885CYP1A2 4394/4885CYP3A4 4551/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | TRPV1 3645/4885CYP1A2 3804/4885CYP3A4 2661/4885 |
| US-20080182894-A1 | METHOD OF PROVIDING PREPARATION FOR TOPICAL APPLICATION AND SUPPLEMENT MEETING CLIENT'S NEEDS | ADH7, ADH4, ADH1B | TRPV1 1732/4885CYP1A2 392/4885CYP3A4 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.